Citations

Clear

382 citation(s) found for "Shapiro, R".

Cell extrinsic alterations in splenic B cell maturation in Flt3‐ligand knockout mice
Dolence, Joseph J., Gwin, Kimberly, Shapiro, Mariya B. , Hsu, Fan‐Chi , Medina, Kay L. , Gwin, Kimberly A, Shapiro, Virginia S, Shapiro, Virginia Smith

Mayo Clinic

Immunity, Inflammation and Disease | April 16, 2015 | Volume: 3 | Issue: 2 | Pages: 103-117

10.1002/iid3.54 | PMID 26029370 Get It

AbstractB lymphopoiesis in bone marrow (BM) is critical for maintaining a diverse peripheral B cell pool to fight infection and establish lifelong immunity. The generation of immature B cells is reduced in Flt3‐ligand (FL‐/‐) mice leading to deficiencies in splenic B cells. Here, we sought to understand the cellular basis of the spleen B cell deficiency in FL‐/‐ mice. Significant reductions in transitional (TS) and follicular (FO) B cells were found in FL‐/‐ mice, and increased frequencies, but not absolute numbers, of marginal zone (MZ) B cells. BAFF‐R expression on splenic B cells and serum levels of B cell activating factor (BAFF) was comparable to wildtype (WT) mice. Mixed BM chimeras revealed that the reductions in TS and FO B cells were cell extrinsic. FL administration into FL‐/‐ mice restored the deficiency in TS B cells and normalized the MZ compartment. Ki67 analysis revealed a significant decrease in the proliferative capacity of TS B cells in FL‐/‐ mice. A Bcl2 transgene did not rescue TS cells in FL‐/‐ mice, uncoupling FL‐deficiency to Bcl2‐dependent survival pathways. Upregulation of CD1d expression and adoptive transfer experiments suggested MZ skewing in FL‐/‐ mice. These findings support an integral role for Flt3 signaling in peripheral B cell maturation.
First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Shapiro, Geoffrey I. , Bell‐McGuinn, Katherine M., Molina, Julian R. , Bendell, Johanna C. , Spicer, James , Kwak, Eunice L., Pandya, Susan , Millham, Robert, Borzillo, Gary , Pierce, Kristen J. , Han, Lixin, Houk, Brett E. , Gallo, Jorge D. , Alsina, María , Braña, Irene , Tabernero, Josep , Tabernero, Josep , Shapiro, Geoffrey I

Mayo Clinic

Clinical Cancer Research | February 4, 2015 | Volume: 21 | Issue: 8 | Pages: 1888-1895

10.1158/1078-0432.ccr-14-1306 | PMID 25652454 Get It

Abstract Purpose: To evaluate safety (primary endpoint), tolerability, pharmacokinetics, pharmacodynamic profile, and preliminary activity of the intravenous, pan-class I isoform PI3K/mTOR inhibitor PF-05212384 in patients with advanced solid tumors. Experimental Design: Part 1 of this open-label phase I study was designed to estimate the maximum-tolerated dose (MTD) in patients with nonselected solid tumors, using a modified continual reassessment method to guide dose escalation. Objectives of part 2 were MTD confirmation and assessment of preliminary activity in patients with selected tumor types and PI3K pathway dysregulation. Results: Seventy-seven of the 78 enrolled patients received treatment. The MTD for PF-05212384, administered intravenously once weekly, was estimated to be 154 mg. The most common treatment-related adverse events (AE) were mucosal inflammation/stomatitis (58.4%), nausea (42.9%), hyperglycemia (26%), decreased appetite (24.7%), fatigue (24.7%), and vomiting (24.7%). The majority of patients treated at the MTD experienced only grade 1 treatment-related AEs. Grade 3 treatment-related AEs occurred in 23.8% of patients at the MTD. No treatment-related grade 4–5 AEs were reported at any dose level. Antitumor activity was noted in this heavily pretreated patient population, with two partial responses (PR) and an unconfirmed PR. Eight patients had long-lasting stable disease (>6 months). Pharmacokinetic analyses showed a biphasic concentration–time profile for PF-05212384 (half-life, 30–37 hours after multiple dosing). PF-05212384 inhibited downstream effectors of the PI3K pathway in paired tumor biopsies. Conclusions: These findings demonstrate the manageable safety profile and antitumor activity of the PI3K/mTOR inhibitor PF-05212384, supporting further clinical development for patients with advanced solid malignancies. Clin Cancer Res; 21(8); 1888–95. ©2015 AACR.
Emerging Role of Cardiovascular CT and MRI in the Evaluation of Stroke
Pagán, Ricardo J. , Parikh, Pragnesh , Mergo, Patricia J. , Gerber, Thomas C., Mankad, Rekha , Freeman, William D. , Shapiro, Brian P. , Freeman, William D , Mankad, Rekha

Mayo Clinic

American Journal of Roentgenology | January 23, 2015 | Volume: 204 | Issue: 2 | Pages: 269-280

10.2214/ajr.14.13051 | PMID 25615749 Get It

Simulation‐based Training for Emergency Medicine Residents in Sterile Technique During Central Venous Catheterization: Impact on Performance, Policy, and Outcomes
Hoskote, Sumedh S. , Khouli, Hassan, Lanoix, Richard, Rose, Keith, Clark, Mark , Chalfin, Donald B. , Shapiro, Janet , Han, Qifa, Aqeel, Adnan

Mayo Clinic

Academic Emergency Medicine | January 1, 2015 | Volume: 22 | Issue: 1 | Pages: 81-87

10.1111/acem.12551 | PMID 25556399 Get It

AbstractObjectivesCentral line–associated bloodstream infection (CLABSI) is a preventable nosocomial infection. Simulation‐based training in sterile technique during central venous catheter (CVC) placement for emergency medicine (EM) residents, and its effect on changing the medical intensive care unit (MICU) practice of routine replacement of CVCs placed under sterile technique in the emergency department (ED), has not been evaluated.MethodsEmergency medicine residents received simulation‐based sterile technique training during CVC placement between May 2008 and September 2010. Between June 2008 and January 2011, the authors reviewed records of patients who had CVCs placed in the ED under sterile technique by EM residents and were admitted to the MICU (group 1) and CVCs placed in the MICU under sterile technique by internal medicine (IM) residents (group 2). IM residents completed similar simulation‐based training before May 2008. Changes in EM residents' sterile technique performance scores were compared, as well as CLABSI rates in both groups. EM residents' CVC procedural skills were not assessed.ResultsSeventy‐six EM residents completed simulation‐based training with significant improvement in performance (median scores 13 out of 24 before training, 24 out of 24 after training; p < 0.001). CLABSI rates per 1,000 catheter‐days were 1.02 in group 1 and 1.02 in group 2 (p = 0.99). Both groups had similar demographics, acuity, and mortality (p > 0.5).ConclusionsRoutine replacement of CVCs placed in the ED under sterile technique after simulation‐based training would appear to be unnecessary. These findings demonstrate patient‐centered outcomes that are comparable for CVCs in ED‐admitted MICU patients, regardless of whether the CVC was placed in the ED or MICU.
Modern Advances in Cardiovascular Imaging: Cardiac Computed Tomography and Cardiovascular Mri in Pericardial Disease
McRee, Chad, Mergo, Patricia J. , Parikh, Pragnesh , Pollak, Amy W., Shapiro, Brian P. , McRee, Chad W

Mayo Clinic

Future Cardiology | December 12, 2014 | Volume: 10 | Issue: 6 | Pages: 769-779

10.2217/fca.14.61 | PMID 25495818 Get It

Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer
Hart, Steven N. , Sharma, Priyanka , Miron, Penelope , Olswold, Curtis, Slettedahl, Seth W. , Hallberg, Emily, Guidugli, Lucia, Davila, Jaime , Beckmann, Matthias W. , Janni, Wolfgang , Rack, Brigitte , Ekici, Arif B. , Slamon, Dennis J. , Konstantopoulou, Irene , Vratimos, Athanassios, Fountzilas, George , Pelttari, Liisa M. , Tapper, William , Durcan, Lorraine , Cross, Simon S. , Pilarski, Robert , Klemp, Jennifer R. , Cox, Angela , Brauch, Hiltrud , Yannoukakos, Drakoulis , Slager, Susan L., Vachon, Celine M. , Eccles, Diana M., Fasching, Peter A. , Eccles, Diana , Wang, Xianshu , Slettedahl, Seth, Davila, Jaime I, Tapper, William J, Shapiro, Charles L. , Klemp, Jennifer, Garber, Judy, Ambrosone, Christine, Couch, Fergus J. , Toland, Amanda Ewart , Olson, Janet E. , Godwin, Andrew K. , Pankratz, V. Shane , Fostira, Florentia , Yao, Song , Garber, Judy E. , Ambrosone, Christine B. , Nevanlinna, Heli , Vachon, Celine M. , Eccles, Diana M., Fasching, Peter A , Pelttari, L M , Eccles, Diana , Konstantopoulou, Irene , Slettedahl, Seth W , Hart, Steven N , Cox, Angela , Ekici, Arif B , Davila, Jaime I , Yannoukakos, Drakoulis , Sharma, Priyanka , Brauch, Hiltrud

Mayo Clinic

Journal of Clinical Oncology | December 2, 2014 | Volume: 33 | Issue: 4 | Pages: 304-311

10.1200/jco.2014.57.1414 | PMID 25452441 Get It

Purpose Recent advances in DNA sequencing have led to the development of breast cancer susceptibility gene panels for germline genetic testing of patients. We assessed the frequency of mutations in 17 predisposition genes, including BRCA1 and BRCA2, in a large cohort of patients with triple-negative breast cancer (TNBC) unselected for family history of breast or ovarian cancer to determine the utility of germline genetic testing for those with TNBC. Patients and Methods Patients with TNBC (N = 1,824) unselected for family history of breast or ovarian cancer were recruited through 12 studies, and germline DNA was sequenced to identify mutations. Results Deleterious mutations were identified in 14.6% of all patients. Of these, 11.2% had mutations in the BRCA1 (8.5%) and BRCA2 (2.7%) genes. Deleterious mutations in 15 other predisposition genes were detected in 3.7% of patients, with the majority observed in genes involved in homologous recombination, including PALB2 (1.2%) and BARD1, RAD51D, RAD51C, and BRIP1 (0.3% to 0.5%). Patients with TNBC with mutations were diagnosed at an earlier age (P < .001) and had higher-grade tumors (P = .01) than those without mutations. Conclusion Deleterious mutations in predisposition genes are present at high frequency in patients with TNBC unselected for family history of cancer. Mutation prevalence estimates suggest that patients with TNBC, regardless of age at diagnosis or family history of cancer, should be considered for germline genetic testing of BRCA1 and BRCA2. Although mutations in other predisposition genes are observed among patients with TNBC, better cancer risk estimates are needed before these mutations are used for clinical risk assessment in relatives.
Immature Recent Thymic Emigrants Are Eliminated by Complement
Hsu, Fan‐Chi , Shapiro, Michael J. , Chen, Meibo W., McWilliams, Douglas C., Seaburg, Lauren, Tangen, Sarah, Seaburg, Lauren M, Tangen, Sarah N, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | November 4, 2014 | Volume: 193 | Issue: 12 | Pages: 6005-6015

10.4049/jimmunol.1401871 | PMID 25367120 Get It

Abstract Recent thymic emigrants (RTEs) must undergo phenotypic and functional maturation to become long-lived mature naive T cells. In CD4-cre NKAP conditional knockout mice, NKAP-deficient RTEs fail to complete T cell maturation. In this study, we demonstrate that NKAP-deficient immature RTEs do not undergo apoptosis, but are eliminated by complement. C3, C4, and C1q are bound to NKAP-deficient peripheral T cells, demonstrating activation of the classical arm of the complement pathway. As thymocytes mature and exit to the periphery, they increase sialic acid incorporation into cell surface glycans. This is essential to peripheral lymphocyte survival, as stripping sialic acid with neuraminidase leads to the binding of natural IgM and complement fixation. NKAP-deficient T cells have a defect in sialylation on cell surface glycans, leading to IgM recruitment. We demonstrate that the defect in sialylation is due to aberrant α2,8-linked sialylation, and the expression of three genes (ST8sia1, ST8sia4, and ST8sia6) that mediate α2,8 sialylation are downregulated in NKAP-defcient RTEs. The maturation of peripheral NKAP-deficient T cells is partially rescued in a C3-deficient environment. Thus, sialylation during T cell maturation is critical to protect immature RTEs from complement in the periphery.
Abstract 4138: Five prognostic subgroups differ in expression of Akt pathway genes: Biomarkers for therapy selection
Joy, Anna , Ramesh, Archana , Bachoo, Robert , Shapiro, William, Smirnov, Ivan V. , Kim, Seungchan , Sarkaria, Jann N. , Ram, Prahlad T. , Mills, Gordon B. , Feuerstein, Burt G.

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 71 | Issue: 8_Supplement | Pages: 4138-4138

10.1158/1538-7445.am2011-4138 Get It

Abstract Biomarkers that select patients for therapeutics would benefit clinical trial design and patient care. The Akt pathway is a therapeutic target in Glioblastoma Multiforme (GBM) and an important determinant of patient outcome. However, it is not known whether activity of this pathway varies among GBM tumors. To investigate we used Akt pathway genes from published GBM expression datasets. We detected 5 patterns of Akt pathway gene expression and these Akt subgroups correlated with prognosis. We analyzed networks within subgroups using both gene set enrichment analysis and a novel method that scores relevance based on both expression and local network connectivity (Komurov et al., PLoS Comput Biol. 2010 6:8, 1-10). The results suggest therapeutic targets within the individual subgroups. Furthermore, preliminary analysis indicates that human GBM xenograft models and primary human GBM manifest similar Akt subgroups. We are investigating rodent xenograft models of Akt subgroups to evaluate subgroup-specific drug sensitivity, and will present a method and examples of analysis integrating gene expression data from human GBM xenografts and primary human GBM. We hypothesize that Akt subgroups will help personalize treatment for GBM therapeutics. Supported by Barrow Neurological Foundation, Halle Family Foundation, and NIH 1 K01 NS064952-01A1 (AMJ). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4138. doi:10.1158/1538-7445.AM2011-4138
Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)
Berry, Donald A. , Cirrincione, Constance, Becker, Heather P., Perez, Edith A. , Martino, Silvana, Kimmick, Gretchen , Burstein, Harold J. , Norton, Larry , Muss, Hyman B. , Hudis, Clifford A. , Shulman, Lawrence N. , Cirrincione, Constance T, O'Regan, Ruth, Shapiro, Charles L. , Schneider, Charles J, Muss, Hyman, O'Regan, Ruth M , Schneider, Charles John , Winer, Eric P. , Norton, Larry

Mayo Clinic

Journal of Clinical Oncology | June 17, 2014 | Volume: 32 | Issue: 22 | Pages: 2311-2317

10.1200/jco.2013.53.7142 | PMID 24934787 Get It

PurposeOptimal adjuvant chemotherapy for early-stage breast cancer balances efficacy and toxicity. We sought to determine whether single-agent paclitaxel (T) was inferior to doxorubicin and cyclophosphamide (AC), when each was administered for four or six cycles of therapy, and whether it offered less toxicity.Patients and MethodsPatients with operable breast cancer with 0 to 3 positive nodes were enrolled onto the study to address the noninferiority of single-agent T to AC, defined as the one-sided 95% upper-bound CI (UCB) of hazard ratio (HR) of T versus AC less than 1.30 for the primary end point of relapse-free survival (RFS). As a 2 × 2 factorial design, duration of therapy was also addressed and was previously reported.ResultsWith 3,871 patients enrolled onto the trial, a median follow-up period of 6.1 years, and 437 RFS events, we achieved an HR of 1.26 (one sided 95% UCB, 1.48; favoring AC does not allow a conclusion of noninferiority of T with AC; UCB > 1.3). With 266 patient deaths, the HR for overall survival (OS) was 1.27 favoring AC (UCB, 1.56). The estimated absolute advantage of AC at 5 years is 3% for RFS (91 v 88%) and 1% for OS (95 v 94%). All nine treatment-related deaths were patients receiving AC and are included in the analyses of both RFS and OS. Hematologic toxicity was more common in patients treated with AC, and neuropathy was more common in patients treated with T.ConclusionThis trial did not show noninferiority of T to AC, a conclusion that is unlikely to change with additional events and follow-up. T was less toxic than AC.
Negative Regulation of TCR Signaling by Linker for Activation of X Cells via Phosphotyrosine-Dependent and -Independent Mechanisms
Shapiro, Michael J. , Nguyen, Chau , Aghajanian, Haig , Zhang, Weiguo , Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | April 18, 2014 | Volume: 181 | Issue: 10 | Pages: 7055-7061

10.4049/jimmunol.181.10.7055 | PMID 18981125 Get It

Abstract The activation of T cells and the initiation of an immune response is tightly controlled through the crosstalk of both positive and negative regulators. Two adaptors that function as negative regulators of T cell activation are adaptor in lymphocytes of unknown function X (ALX) and linker for activation of X cell (LAX). Previously, we showed that T cells from mice deficient in ALX and LAX display similar hyperresponsiveness, with increased IL-2 production and proliferation upon TCR/CD28 stimulation, and that these adaptors physically associate. In this study, we analyze the nature of the association between ALX and LAX. We demonstrate that this association occurs in the absence of TCR/CD28 signaling via a mechanism independent of both tyrosine phosphorylation of LAX and the SH2 domain of ALX. Cotransfection of ALX with LAX resulted in LAX tyrosine phosphorylation in the absence of TCR/CD28 stimulation. ALX-mediated LAX phosphorylation depends upon the ALX SH2 domain, which functions to recruit Lck to LAX. We also show that LAX, like ALX, can inhibit RE/AP reporter activation. However, in contrast to its inhibition of NFAT, the inhibition of RE/AP by LAX is independent of its tyrosine phosphorylation. Therefore, it can be concluded that inhibition of signaling events involved in T cell activation by LAX occurs through mechanisms both dependent on and independent of its tyrosine phosphorylation.